Identification and Characterisation of Infiltrating Immune Cells in Malignant Pleural Mesothelioma Using Spatial Transcriptomics

Increasing evidence strongly supports the key role of the tumour microenvironment in response to systemic therapy, particularly immune checkpoint inhibitors (ICIs). The tumour microenvironment is a complex tapestry of immune cells, some of which can suppress T-cell immunity to negatively impact ICI therapy. The immune component of the tumour microenvironment, although poorly understood, has the potential to reveal novel insights that can impact the efficacy and safety of ICI therapy. Successful identification and validation of these factors using cutting-edge spatial and single-cell technologies may enable the development of broad acting adjunct therapies as well as personalised cancer immunotherapies in the near future. In this paper we describe a protocol built upon Visium (10x Genomics) spatial transcriptomics to map and characterise the tumour-infiltrating immune microenvironment in malignant pleural mesothelioma. Using ImSig tumour-specific immune cell gene signatures and BayesSpace Bayesian statistical methodology, we were able to significantly improve immune cell identification and spatial resolution, respectively, improving our ability to analyse immune cell interactions within the tumour microenvironment.

[1]  R. Vento-Tormo,et al.  An introduction to spatial transcriptomics for biomedical research , 2022, Genome Medicine.

[2]  L. Pachter,et al.  Museum of spatial transcriptomics , 2020, Nature Methods.

[3]  N. Girard,et al.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  G. Ahlenstiel,et al.  Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes , 2021, Cancers.

[5]  Raphael Gottardo,et al.  Spatial transcriptomics at subspot resolution with BayesSpace , 2021, Nature Biotechnology.

[6]  G. Ahlenstiel,et al.  Immune-checkpoint inhibitors for advanced hepatocellular carcinoma: a synopsis of response rates. , 2021, The oncologist.

[7]  Xing Huang,et al.  Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy , 2021, Signal Transduction and Targeted Therapy.

[8]  A. Mansfield,et al.  First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial , 2021, The Lancet.

[9]  V. Marx Method of the Year: spatially resolved transcriptomics , 2021, Nature Methods.

[10]  Raphael Gottardo,et al.  Integrated analysis of multimodal single-cell data , 2020, Cell.

[11]  X. Solé,et al.  Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification , 2019, Journal for ImmunoTherapy of Cancer.

[12]  S. O’Donoghue,et al.  Single-cell transcriptomics reveals involution mimicry during the specification of the basal breast cancer subtype. , 2021, Cell reports.

[13]  C. Robert A decade of immune-checkpoint inhibitors in cancer therapy , 2020, Nature Communications.

[14]  Joseph Bergenstråhle,et al.  Spatially Resolved Transcriptomes—Next Generation Tools for Tissue Exploration , 2020, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  J. Larkin,et al.  Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  E. Taioli,et al.  Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use , 2020, Translational lung cancer research.

[17]  O. Molinier,et al.  Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial , 2019, Clinical Cancer Research.

[18]  Barbara B. Shih,et al.  Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors , 2018, Cancer Immunology Research.

[19]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[20]  F. Gemignani,et al.  Overexpressed genes in malignant pleural mesothelioma: implications in clinical management. , 2018, Journal of thoracic disease.

[21]  Ross A Soo,et al.  De-novo and acquired resistance to immune checkpoint targeting. , 2017, The Lancet. Oncology.

[22]  M. Suarez‐Almazor,et al.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.

[23]  N. Agarwal,et al.  Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers , 2017, Front. Oncol..

[24]  Jaakko Astola,et al.  Generalized Hampel Filters , 2016, EURASIP J. Adv. Signal Process..

[25]  T. Barnetche,et al.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis , 2015, BMC Medicine.